secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020819
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics reports Q1 2023 net loss of $18.4M; cash at $39.8M
-------------------------------------------------------------------------

- Cash, equivalents, marketable securities, restricted cash totaled $39.8M as of March 31, 2023.
- Revenue of $0.2M from Immedica Pharma license/supply agreement for pegzilarginase in Europe/Middle East.
- R&D expenses fell to $13.8M from $17.0M; G&A expenses fell to $5.2M from $8.8M year-over-year.
- Net loss improved to $18.4M from $24.4M in Q1 2022; includes $1.7M non-cash stock compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/0000950170-23-020819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/agle-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer